We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACGN
3051
DELISTED
Aceragen Inc
ACGN
-3,556
Closed -$62K
KDNY
3052
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
-11,893
Closed -$152K
VRAY
3053
DELISTED
ViewRay, Inc.
VRAY
-11,570
Closed -$83K
BRMK
3054
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
-11,027
Closed -$109K
AUD
3055
DELISTED
Audacy, Inc.
AUD
-10,072
Closed -$37K
BBBY
3056
PUT
DELISTED
Bed Bath & Beyond Inc
BBBY
-16,400
Closed -$1.03M
ATNX
3057
DELISTED
Athenex, Inc. Common Stock
ATNX
-2,164
Closed -$130K
LCI
3058
DELISTED
Lannett Company, Inc.
LCI
-8,400
Closed -$101K
OYST
3059
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
-17,028
Closed -$202K
VELOU
3060
DELISTED
Velocity Acquisition Corp. Units
VELOU
-33,986
Closed -$342K
LOTZ
3061
DELISTED
CarLotz, Inc. Class A Common Stock
LOTZ
-44,263
Closed -$169K
ELOX
3062
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
-568
Closed -$37K
LMACU
3063
DELISTED
Liberty Media Acquisition Corporation Unit
LMACU
-10,040
Closed -$104K
TMBR
3064
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
-2,694
Closed -$123K
PING
3065
DELISTED
Ping Identity Holding Corp.
PING
-11,525
Closed -$283K
NBEV
3066
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
-52,243
Closed -$73K
ATC
3067
DELISTED
Atotech Limited
ATC
-1,408,180
Closed -$34M
SBEAU
3068
DELISTED
SilverBox Engaged Merger Corp I Units
SBEAU
-33,971
Closed -$338K
SC
3069
DELISTED
SANTANDER CONSUMER USA HOLDINGS INC
SC
-15,516
Closed -$647K
RDS.A
3070
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
-13,700
Closed -$611K
MRLN
3071
DELISTED
Marlin Business Services Corp
MRLN
-198,251
Closed -$4.41M
DRNA
3072
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
-2,682,596
Closed -$54.1M
COR
3073
DELISTED
Coresite Realty Corporation
COR
-20,240
Closed -$2.8M
ZIXI
3074
DELISTED
Zix Corporation
ZIXI
-28,563
Closed -$202K
ADXS
3075
DELISTED
Advaxis Inc
ADXS
-166,748
Closed -$87K

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.